The global branded generics market size is expected to register a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the introduction of new medical practices and entry of new market players.
Branded generics are types of generic drugs whose names are assigned by the original drug manufacturing company rather than focusing on the chemical name of the drugs components. These types of drugs are primarily developed by the original drug developer after the expiration of drugs patent and the branded name of the drugs remained under the control of the original company. However, generic drugs can be available in different brand names but they normally have the same chemical components or active ingredients with the branded drug. Various extrinsic dynamics and internal relating to marketing, manufacturing, and licensing characterize the pharmaceutical industry, which presents a key aspect for the market expansion.
Branded drugs refers to patented drugs, which is the result of pharmaceutical company filing for a patent when they discover new drug. Branded generics are versions of products sold by manufacturers that build brand for their generic segments. These generics drugs are also referred to as value-added generics and are different from commodity generics of pharmaceutical products. These drugs are mainly used as a substitute to innovative products when the patent expires.
The report on the global branded generics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Branded Generics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Value-added & Trade Named Generics), Applications (Cardiovascular, Anti-cancer, CNS, and Anti-infective), Distribution Channels (Hospital Pharmacy, Clinics, Pharmacy, and Drug Stores) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Bausch Health; Mylan N.V.; Cadila Healthcare; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Apotex Inc.; Bausch Health; Cadila Healthcare; Sandoz Private Limited; GlaxoSmithKline Pharmaceuticals Limited; AstraZeneca plc.; Par Pharmaceutical Companies, Inc.; Lupin Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd. |
Based on products, the global branded generics market consists of value-added & trade named generics. The value-added & trade named generics segment accounted for a key share of the market in 2020 and is expected to grow at a rapid pace due to large number of pharmaceutical products and increasing competition for advancement of highly effective generic drugs.
On the basis of applications, the market is divided into cardiovascular, anti-cancer, CNS, and anti-infective. The cardiovascular (CVS) segment is projected to expand at a considerable CAGR during the forecast period due to rising cases of the expiry of CVS drugs patents and increasing demand for effective treatment of heart-related diseases. Meanwhile, the CNS segment is anticipated to expand at substantial growth during the forecast period owing to growth of patent expiry of several key antipsychotics and antidepressants.
Based on distribution channels, the global branded generics market is divided into hospital pharmacy, clinics, pharmacy, and drug stores. The hospital pharmacy segment is expected to expand at a robust growth rate during the projected period due to wide availability of innovative pharmaceutical products in hospital pharmacies. On the other hand, the clinics segment is anticipated to expand at a rapid pace during the forecast period due to increasing number of patients visit in clinics due to easy accessibility and low cost.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the targeted period due to the increasing demand for cost-effective medicines and early adoption of advanced methods for drug discovery in the region. The market of Asia Pacific, however, is anticipated to exhibit a healthy growth rate during the forecast period owing to increasing healthcare infrastructure and government funding in the region.
Segments Covered in the Report
The global branded generics market has been segmented on the basis of
Products
Applications
Distribution Channels
Regions
Key Players
Key players competing in the global branded generics market are Bausch Health; Mylan N.V.; Cadila Healthcare; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Apotex Inc.; Bausch Health; Cadila Healthcare; Sandoz Private Limited; GlaxoSmithKline Pharmaceuticals Limited; AstraZeneca plc.; Par Pharmaceutical Companies, Inc.; Lupin Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd. The main market players are continuously engaged in a range of the market development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market share in the long run.
Some other reports from this category!